Director, Legal Department, Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, Poland. Graduate of the Legal and Administration Department, University of Warsaw, Poland
During most of her professional career she has been involved in international health issues, especially in collaborative projects with the United States, Canada and the World Health Organization.
Since the accession of Poland to the European Union in 2004 she has been representing Poland as an expert in the Council Working Party on Pharmaceuticals and Medical Devices working on the EU pharmaceutical legislation proposals, she has also participated in the activities of the Heads of Agencies and has been a member of EMACOLEX.
Executive Vice President Vaccines, Sanofi, France
Olivier Charmeil is a graduate of HEC (Ecole des Hautes Etudes Commerciales) and of the Institut d’Etudes Politiques in Paris. From 1989 to 1994, he worked in the Mergers & Acquisitions department of Banque de l’Union Européenne. He joined Sanofi Pharma in 1994 as head of Business Development. Subsequently, he held various posts within the Group, including Chief Financial Officer (Asia) for Sanofi-Synthélabo in 1999 and Attaché to the Chairman, Jean-Francois Dehecq, in 2000, before being appointed as Vice President, Development within the Sanofi-Synthélabo International Operations Directorate, where he was responsible for China and support functions.
In 2003, Olivier Charmeil was appointed Chairman and Chief Executive Officer of Sanofi-Synthélabo France, before taking the post of Senior Vice President, Business Management and Support within the Pharmaceutical Operations Directorate. In this role, he piloted the operational integration of Sanofi-Synthélabo and Aventis. He was appointed Senior Vice President Asia/Pacific, Pharmaceutical Operations in February 2006 and since January 1, 2008, Operations Japan have reported to him, as have Asia/Pacific and Japan Vaccines since February 2009. Since January 1, 2011, Olivier Charmeil has served as Executive Vice President Vaccines and as a member of the Executive Committee.
Olivier Charmeil became the International Federation Pharmaceutical Manufacturers & Associations (IFPMA) representative on the GAVI Board on 1st August 2014. This nomination also bestows the chairmanship of the CEO Steering Committee of IFPMA uniting the CEOs of the member companies (GSK, Merck, Johnson & Johnson, Pfizer, Takeda, Novartis and Daiichi Sankyo).”